Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 40 clinical trials
A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

This phase III trial compares the effects of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone in treating patients with newly diagnosed primary mediastinal B-cell lymphoma (PMBCL). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of cancer cells …

  • 24 Oct, 2022
  • 100 locations
Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia

This randomised controlled trial will determine the non-inferiority of stopping empiric antibiotics prior to absolute neutrophil count (ANC) recovery (Early Stopping) versus stopping antibiotics

  • 12 Dec, 2021
  • 1 location
Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel (MP-PDAC-01)

ULN absolute neutrophil count (ANC) ≥ 1,500 cells/µL platelet count ≥ 100,000/µL hemoglobin ≥ 9.0 g/dL Subjects who have at least a

biliary stents
neutrophil count
  • 29 Jun, 2022
  • 1 location
PEG-ASP+Gemox Regimen and Thalidomide for NK/T Lymphoma

Extranodal natural killer/T-cell lymphoma (ENKTL) is an aggressive form of non-Hodgkin's lymphoma and shows extremely poor survival. This prospective pilot study to evaluate the efficacy and safety of long-acting aspargase (pegylated aspargase, PEG-ASP) combined with gemcitabine and oxaliplatin (PASP -Gemox) treatment in this population.

  • 22 Mar, 2021
  • 1 location
Fast-track Blood Test for Suspected Fever by Deficiency of a Kind of White Blood Cells As Main Defense Against Infection (FRANCiS-NF)

This is a comparative study for adult participants with cancer who are suspected to have neutropenic fever (or fever with low neutrophil count) in emergency department. Neutrophil is a kind of defensive white blood cell combating against infection, especially by bacteria and fungi. Low neutrophil can be part of the …

  • 11 Jul, 2022
  • 1 location
Switch to Oral Antibiotics in Gram-negative Bacteremia (SOAB)

, central nervous system infection, terminal illness with expected survival less than 14 days, absolute neutrophil count less than 1,000/ml and hematopoietic or solid organ transplantation within the

  • 18 Apr, 2022
  • 7 locations
Non-inferiority Trial of Locally Manufactured Typhoid Conjugate Vaccine 'Typhocon' in Bangladesh

differential for white blood count, hemoglobin, absolute neutrophil count, platelet count, serum alanine transaminase, serum creatinine) on day -7 to day -2 for screening of participants before vaccination and

Accepts healthy volunteers
  • 07 Oct, 2022
  • 1 location
Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation

This is a Phase 2, open-label, multi-center study to evaluate the efficacy and the safety/tolerability of poziotinib in seven patient cohorts for up to 603 previously treated and treatment-naïve NSCLC patients. Cohorts 3 and 4 were added with Amendment 1 and three additional cohorts were added with Amendment 2 (Cohorts …

lung carcinoma
stage iv non-small cell lung cancer
  • 09 Mar, 2022
  • 51 locations
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation

subject's choice. The intervention will begin approximately 10 days prior to stem cell infusion and will continue until the first day of neutrophil engraftment (first day absolute neutrophil count >500

mantle cell lymphoma
stem cell infusion
neutrophil count
multiple myeloma
cell transplantation
  • 29 Apr, 2022
  • 1 location
Sitagliptin for Prevention of aGVHD After Alternative Donor Transplatation

absolute neutrophil count and platelets. To evaluate the incidence of CMV, EBV and other infections occurring during the 100 days post-transplant. To study non-relapse mortality (NRM) at

  • 24 Mar, 2022
  • 1 location